Drugs / M72/AS01E-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06062238 | Mar 2024 → Apr 2028 expected | tuberculosis | Gates Medical Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M72/AS01E-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06062238 ↗ |
| Modality | Vaccine | “M72/AS01E-4 Mtb vaccine” NCT06062238 ↗ |
| Route | Intramuscular | “when administered intramuscularly (IM)” NCT06062238 ↗ |